Sandrock Alfred 4

4 · Voyager Therapeutics, Inc. · Filed Feb 10, 2026

AI-generated summary of this filing

Updated Feb 10, 2026

Voyager (VYGR) CEO Alfred Sandrock Receives Equity Awards

What Happened

Alfred Sandrock, President, CEO and a director of Voyager Therapeutics (VYGR), received equity grants on Feb 6, 2026: 86,250 restricted stock units (RSUs) and a stock option/derivative covering 402,500 shares. Both grants show an acquisition price of $0 (these are compensation awards, not open‑market purchases).

Key Details

Transaction date: Feb 6, 2026; Form 4 filed Feb 10, 2026 (timely filing).
RSUs: 86,250 RSUs awarded (F1). Each RSU converts to one share upon vesting; grant price $0.
Option/derivative: 402,500-share option/award (listed as a derivative acquisition) (F3); grant price $0.
Additional note (F2): Reporting person acquired 5,000 shares under the company ESPP since the last Form 4.
Vesting summary:
- RSUs vest over 3 years (1/3 after 1 year, then 1/3 each year thereafter; vesting commencement = Feb 6, 2026) (F1).
- Option vests over 4 years, with 1/48th vesting one month after Feb 6, 2026 and monthly thereafter (F3).
Shares owned after the transactions were not specified in the provided excerpt.

Context

These are compensation grants (awards), not sales or open‑market purchases — they represent future economic interest subject to vesting and continued service. The option grant is not an exercise; it grants the right to buy shares in the future according to the vesting schedule. The RSUs will convert to actual shares only as they vest.

Form 4

Period: 2026-02-06

DirectorPresident and CEO

Transactions

Award
Common Stock
[F1][F2]
2026-02-06+86,250→ 522,181 total
Award
Stock Option (Right to Buy)
[F3]
2026-02-06+402,500→ 402,500 total
Exercise: $3.68Exp: 2036-02-06→ Common Stock (402,500 underlying)

Footnotes (3)

[F1]Consists of shares of common stock issuable under an aggregate of 86,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
[F2]Includes 5,000 shares of common stock acquired under the Voyager Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4.
[F3]This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

Signature

/s/ Gregory Shiferman, as Attorney-in-Fact for Alfred Sandrock|2026-02-10

1 file